TipRanks
Crispr Therapeutics AG (MX:CRSPN)
:CRSPN
Mexico Market
CRSPN
Crispr Therapeutics AG
RESEARCH TOOLSreports

Crispr Therapeutics AG (CRSPN) Stock News & Sentiment

0 Followers
Snowflake, Palo Alto, Dell, GameStop, Crispr Insider Shock
Premium
Weekend Updates
Snowflake, Palo Alto, Dell, GameStop, Crispr Insider Shock
6d ago
GME
CRSP
Cathie Wood Sells $28.6M of Alphabet Stock and Buys $26.4M of Meta Shares. What Else Is She Buying?
Premium
Market News
Cathie Wood Sells $28.6M of Alphabet Stock and Buys $26.4M of Meta Shares. What Else Is She Buying?
22d ago
TEM
BEAM
Crispr Therapeutics Maintained at Buy as Lp(a) Program Prospects Support Unchanged $88 Price Target
Premium
Ratings
Crispr Therapeutics Maintained at Buy as Lp(a) Program Prospects Support Unchanged $88 Price Target
25d ago
CRSP
CRISPR Therapeutics: Buy Rating Reiterated, $80 Price Target Maintained Ahead of Key HORIZON Catalyst
Premium
Ratings
CRISPR Therapeutics: Buy Rating Reiterated, $80 Price Target Maintained Ahead of Key HORIZON Catalyst
2M ago
CRSP
Analyst Maintains Buy on CRISPR Therapeutics as Casgevy Ramp and Diversified Pipeline Strengthen Long-Term Growth Outlook
Premium
Ratings
Analyst Maintains Buy on CRISPR Therapeutics as Casgevy Ramp and Diversified Pipeline Strengthen Long-Term Growth Outlook
2M ago
CRSP
Crispr Therapeutics: Strong Casgevy Uptake, Expanding Pipeline and Cash Runway Support Unchanged $82 Price Target and Buy Rating
Premium
Ratings
Crispr Therapeutics: Strong Casgevy Uptake, Expanding Pipeline and Cash Runway Support Unchanged $82 Price Target and Buy Rating
2M ago
CRSP
Casgevy Momentum and Pipeline Catalysts Drive Yigal Nochomovitz to Maintain Buy Rating and Raise Price Target to $88
Premium
Ratings
Casgevy Momentum and Pipeline Catalysts Drive Yigal Nochomovitz to Maintain Buy Rating and Raise Price Target to $88
2M ago
CRSP
More MX:CRSPN News >

CRSPN News on the Web

Snowflake, Palo Alto, Dell, GameStop, Crispr Insider Shock
TipRanks News
Neutral
CRISPR Therapeutics (CRSP) Shares Dip Amid Anthropic AI Enzyme Discovery, Highlighting ...
GuruFocus News
Bearish
Claude discovers novel enzyme system with CRISPR-like repeats
TipRanks News
Bullish
3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026
The Motley Fool
Bullish
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise?
The Motley Fool
Bullish
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Zacks
Neutral
CRISPR Therapeutics AG at Morgan Stanley Global Healthcare Conference Transcript
GuruFocus News
Neutral
CRISPR Therapeutics (CRSP) Shows Modest Recovery Amid High Price-to-Sales Valuation
GuruFocus News
Neutral

News Score - Last 7 Days

Neutral
MX:CRSPN
Sector Average
Media Buzz
This Week2 articles
Weekly Average8.25 articles
News Sentiment
This Week50%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

FAQ

What is MX:CRSPN’s Media Buzz Sentiment?
2 articles about MX:CRSPN were published this week. In an average week, 8.25 articles are published.
    What is MX:CRSPN’s weekly average amount of articles?
    In an average week, 8.25 articles about MX:CRSPN are published.
      What is MX:CRSPN’s News Sentiment?
      50% of articles about MX:CRSPN were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        HUMHumana
        ACETAdicet Bio
        ZYMEZymeworks
        RHHBYRoche Holding
        QTTBQ32 Bio
        Showing the stocks with the most bullish news sentiment over the past week